HLA-DRA and cancer: Although GC BLOW tumors showed increased levels of genes involved in antigen presentation, including markers for conventional type 1 DCs (i.e., BATF3 and ITGAX/CD11c) and genes encoding MHC class II molecules (i.e., HLA-DMB, HLA-DPB1 and HLA-DRA), low expression of GC B signature was coupled to the upregulation of genes encoding inhibitory checkpoint molecules, such as PDCD1LG2 (encoding PD-L2), HAVCR2 (better known as TIM3) and CD276 (also known as B7-H3) (Fig. 5A and Table S4), which expression (by cancer or immune cells) has been linked to immunosuppression in several cancer types [45–47].